Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and
anti-tumor activity of AK119 combined with AK104 in tumor patients.